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2  Abstract Pre-synaptic secretion of brain-derived neurotrophic factor (BDNF) from noradrenergic neurons may protect the Alzheimer’s disease (AD) brain from amyloid pathology. While the BDNF polymorphism (rs6265) is associated with faster cognitive decline and increased hippocampal atrophy, a replicable genetic association of BDNF with AD risk has yet to be demonstrated. This could be due to masking by underlying epistatic interactions between BDNF and other loci that encode proteins involved in moderating BDNF secretion (DBH and Sortilin). We performed a multi-cohort case-control association study of the BDNF, DBH and SORT1 loci comprising 5,682 controls and 2,454 AD patients from Northern Europe (87% of samples) and Spain (13%). The BDNF locus was associated with increased AD risk (odds ratios; OR=1.1-1.2, p=0.005-0.3), an effect size that was consistent in the Northern European (OR=1.1-1.2, p=0.002-0.8) but not the smaller Spanish (OR=0.8-1.6, p=0.4-1.0) subset. A synergistic interaction between BDNF and sex (synergy factor; SF=1.3-1.5 p=0.002-0.02) translated to a greater risk of AD associated with BDNF in women (OR=1.2-1.3, p=0.007-0.00008) than men (OR=0.9-1.0, p=0.3-0.6). While the DBH polymorphism (rs1611115) was also associated with increased AD risk (OR=1.1, p=0.04) the synergistic interaction (SF=2.2, p=0.007) between BDNF (rs6265) and DBH (rs1611115) contributed greater AD risk than either gene alone, an effect that was greater in women (SF=2.4, p=0.04) than men (SF=2.0, p=0.2). These data support a complex genetic interaction at loci encoding proteins implicated in the DBH-BDNF inflammatory pathway that modifies AD risk, particularly in women.  
3  Keywords “Epistasis, Genetic”, “Neurotrophins”, “Alzheimer disease”, “Brain-Derived Neurotrophic Factor”, “Dopamine beta-Hydroxylase”, “Sortilin” Introduction  Understanding the genetic factors that modify risk and/or progression of Alzheimer’s disease (AD) is fundamental for the identification and monitoring of at-risk individuals and could lead to novel therapeutic targets and biomarkers. Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the brain and is a well-characterised protective factor against AD pathology. Specifically, it has been reported that pre-synaptic secretion of BDNF from noradrenergic neurons modulates neural circuitry, synaptic plasticity, neuronal survival and differentiation and protects neurons from various types of insult (reviewed in [1]). In accordance with these findings, reduced levels of BDNF (mRNA and protein) have been observed in peripheral blood of AD patients [2] and in cortical and subcortical brain regions of individuals with AD at autopsy [3, 4]. In the aged population and in subjects with mild cognitive impairment and AD patients, reduced brain BDNF levels correlate with lower cognitive scores and faster cognitive decline [5-7]. Moreover, there is some evidence that genetic variation at the BDNF locus may moderate downstream effects of the pathological protein, β-amyloid, in autosomal dominant AD. For example, asymptomatic adults with signs of brain amyloidosis who carry the methionine allele at rs6265 show faster decline in episodic memory, lower hippocampal volume and increased tau markers in cerebrospinal fluid compared to valine homozygotes [8-12]. This could be attributed to the association of this allele with altered intracellular trafficking and reduced secretion of BDNF [13-15]. Additionally, there is evidence that the protective effect of lifetime 
4  exposure to cognitively stimulating activities on cognitive performance may be weaker in carriers of the methionine allele [16]. Thus, the methionine allele may be a prognostic biomarker for predicting cognitive decline due to AD. That being said, extensive study in over 30 populations (Caucasian, Asian, African and mixed) has failed to demonstrate a replicable association of BDNF genetic variants with altered AD risk (www.Alzgene.org [17]). Studies using rodent models have shown that a reduction in BDNF levels may precede the appearance of amyloid plaque pathology [18]. Reduced BDNF levels have been associated with altered synaptic plasticity [19-21], increased cortical amyloid plaque numbers, and reduced noradrenergic innervation of the hippocampus, frontal cortex, and cerebellum [22] of animal models, effects that can be reversed with BDNF treatment [23-27].  Taken together, data from animal and human studies strongly support an important neuroprotective effect of BDNF and that an imbalance in BDNF signalling may be an early event in AD pathogenesis. It follows that modulation of BDNF secretion could be critical to this process. In this regard, previous studies using rodent models have reported a feed forward loop between BDNF and the noradrenergic system, whereby noradrenaline (norepinephrine) induces astrocytic and neuronal BDNF secretion, which in turn stimulates noradrenergic signalling as part of an anti-inflammatory mechanism [28-32]. In support of this, reduced noradrenaline levels have also been reported in aged and AD brains and it has been hypothesised that increasing noradrenergic signalling in the brain could halt the progression of neurodegeneration and cognitive decline (reviewed in [33]). Noradrenaline is synthesised from dopamine, a reaction catalysed by dopamine beta-hydroxylase (DBH) and is an anti-inflammatory agent that can attenuate 
5  the cortical inflammatory response to the Aβ42 peptide [34]. Thus deregulation of DBH-mediated synthesis of noradrenaline could have downstream effects on BDNF secretion. An additional factor in BDNF secretion is the intracellular sorting of BDNF to the secretory pathway, which is regulated by binding of the BDNF pro-domain to the luminal domain of Sortilin [35]. This interaction prevents BDNF degradation, targets BDNF to the secretory pathway [36] and facilitates the release of mature BDNF [37].  The aims of this first study of Stage 2 of the Epistasis Project (the results of Stage 1 [38-44] are summarised in Table 1), were to further evaluate the contribution of genetic variation at the BDNF locus to AD risk in a large case-control dataset (n=8,136) and determine whether the association could be masked by genetic epistasis between BDNF variants and sex, age, APOE ε4 status and variants at loci encoding proteins that control BDNF secretion (DBH and Sortilin).  Materials and Methods Study population DNA samples were collected from individuals of Caucasian European descent by seven research centres within two geographical regions namely, Northern Europe (Bristol, Nottingham, OPTIMA and Rotterdam) and Spain (Madrid, Oviedo and Santander). All AD cases were diagnosed “definite” or “probable” by CERAD or NINCDS-ADRDA criteria. AD cases were sporadic, i.e. possible autosomal dominant cases were excluded, based on family history. The cohorts in Stage 1 of the Epistasis Project were described in [38]. In this Stage 2, the Bonn cohort was replaced by that from Madrid, giving a better overall balance between Northern Europe and Spain. The Madrid cohort fulfilled our criteria of an all-Caucasian population drawn from a narrow geographical region. The demographics of each sample collection are shown in Table 2. Research ethics 
6  approval was obtained by each of the participating groups. Written informed consent was given for donation of blood samples from all participants, or their legal representatives.  Polymorphism selection We downloaded Caucasian European (CEU) population data from the HaploView platform (release 27) using gene coordinates (gene +/- 10kbp flanking regions) extracted from the UCSC MySQL server (hg18) at https://genome.ucsc.edu/. Polymorphisms with a genotype rate <50%, and that were in Hardy-Weinberg equilibrium (p<0.001) and with a minor allele frequency (MAF) <5% were removed. The remaining polymorphisms were introduced into the tagger function in HaploView. A tagging threshold of r2>0.8 and log odds (LOD) score>3.0 was used. The “Aggressive Tagging” approach was implemented, which allows a haplotype of up to three polymorphisms to be used as a proxy. We identified 34 polymorphisms (5 in BDNF, 23 in DBH and 6 in SORT1) that have a minor allele frequency >5% in Caucasian Europeans and that cover 80% of the variation  in these genes (Table 3). Due to the considerable variation in DBH, coverage of this gene was restricted to rs1611115, which has previously been associated with increased AD risk in men aged <75 [39] and is responsible for 30-50% of the considerable variation in DBH activity [46-53]. The 12 polymorphisms were taken forward for genotyping.  Genotyping and imputation Genotyping for all centres except Rotterdam (below) was performed by LGC (Hoddesdon, Hertfordshire, UK), using the KASPar technology by KBioscience http://www.kbioscience.co.uk. Six to eight duplicate samples and one blank (H2O) sample were included on each plate. All blank samples were negative. The concordance 
7  between duplicates was 100% with the exception of one discordant sample for BDNF rs11030104 in the Bristol dataset, which was removed from analyses. Where data were available from previous in-house TaqMan genotyping, LGC genotypes were 100% concordant (BDNF rs6265; n=483, DBH rs1611115; n=396). Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA).  Genotypes for the Rotterdam cohort were imputed from whole genome data using MACH software (http://www.sph.umich. edu/csg/abecasis/MACH/) and with the 1000 genomes project (phase I version 3 reference panel, positive strand) as a reference. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped. In order to allow analysis alongside the genotyped cohorts, the imputed probabilities from Rotterdam were converted to genotypes such that a value of 0 was coded as homozygote for allele 2, a value of 1 was coded as heterozygote and a value of 2 was coded as homozygote for allele 1. It should be noted that a dosage of 1 could be heterozygote, but it could also mean that person has a 0.5 probability of being homozygote for allele 1 and a 0.5 probability of being homozygote for allele 2. That being said, it is commonplace in genetics to round these values to 0/1/2 with the implied corresponding genotypes. The supplementary table shows the genotype counts and allele frequencies as well as genotyping rate for all individual centres. The genotyping rate for each polymorphism ranged from 0.99 to 1.00 in the total dataset. All genotypes were confirmed to be in Hardy-Weinberg equilibrium (α=0.001) in controls from all individual centres. APOE ε4 genotypes were determined according to the genotypes at rs429358 and rs7412. Tests for pair-wise intragenic linkage disequlibrium for the 5 BDNF polymorphisms and the 6 
8  SORT1 polymorphisms were consistent with the Haploview data (r<0.8) with the exception of rs6265 and rs11030104 in BDNF (r2=0.9) and rs2228604 and rs10745354 in SORT1 (r2=1.0). The high degree of co-inheritance of these pairs was replicated in both the Northern European and Spanish controls. The polymorphisms rs11030104 (BDNF) and rs10745354 (SORT1) were therefore removed from the study as they provided no further information. Statistical analyses All analyses were performed in R version 3.5.0 [54]. The relative risk (odds ratios and 95% confidence intervals; CI) for AD was calculated for each of the 10 polymorphisms brought forward for analysis using a general linear model for dominant and recessive inheritance models controlling for age-at-extraction, sex, APOE ε4 allele and individual centre. The Akaike Information Criterion (AIC) was used to compare goodness-of-fit, with smaller values of AIC corresponding to preferable models. The statistical power for each sample included in the study to detect a significant (α=0.05) association of a polymorphism with a minor allele frequency 0.2 (mean of polymorphisms included in the study) with AD risk (OR=1.2) under a dominant model and assuming a prevalence of AD of 10% in the population aged over 65 is as follows: Total dataset 97%, Northern Europe 92% (Bristol 14%, Nottingham 14%, OPTIMA 17%, Rotterdam 78%), Spain 31% (Madrid 18%, Oviedo 11%, Santander 13%). All tests were first performed in the total dataset and subsequently stratifying by geographical region:  Northern Europe=Bristol, Nottingham, OPTIMA and Rotterdam; Spain=Madrid, Oviedo and Santander. When an association (p<0.05) was observed in the Northern European dataset, analyses were subsequently tested in the Rotterdam subset as the only collection centre with sufficient statistical power to detect an association. Interactions were 
9  assessed using the Synergy Factor (SF) described in [55]. Using this method, the SF=actual OR (joint effect of two factors) / predicted OR (product of the OR for each factor alone). The null hypothesis states that the actual OR is equal to the predicted OR. This method assesses interactions on a multiplicative scale rather than an additive scale. Throughout the study, significance was considered at the α=0.05 level. However, due to the large number of tests performed (n=224 in total), the Bonferroni cut-off (α=0.0002) can be considered as a more stringent cut-off for significance that minimizes the false-positive associations reported. Associations that surpass this cut-off are indicated in the text and figures. Results Genetic variation at the BDNF locus is associated with increased AD risk We tested for association of the 4 BDNF polymorphisms with altered AD risk in the total population. The model preferred (lowest AIC) for BDNF1 was the recessive inheritance model, whereas the preferred models for BDNF2-4 were the dominant models. The OR and 95% CI for the preferred models of each polymorphism are plotted in Fig1. The BDNF1 polymorphism, previously shown to regulate BDNF trafficking, was not associated (at the α=0.05 level) with altered AD risk in the total (rs6265 MM; OR=1.2, p=0.3), Northern European (OR=1.0, p=0.8) or Spanish (OR=1.6, p=0.1) datasets (Fig1A). However, the OR in the total dataset was of a similar yet greater magnitude to those for BDNF2 (Fig1B; rs12288512 A allele OR=1.1, p=0.04) and BDNF3 (Fig1C; (rs113030102 G allele OR=1.1, p=0.005), associations which surpassed our cut-off for significance. Both BDNF2 (OR=1.2, p=0.01) and BDNF3 (OR=1.2, p=0.005) were associated with increased AD risk in the Northern European but not Spanish (OR<1.0, p>0.3) populations. The associations of BDNF2-4 were even 
10  stronger in the Rotterdam subset (BDNF2; OR=1.2, p=0.002, BDNF3; OR=1.3, p=0.0008). Another polymorphism, BDNF4 (Fig1D), that was not significant in the total dataset (p=0.08) despite a similar OR (rs11030119 A+; OR=1.1), was associated with increased AD risk in the Northern European (OR=1.2, p=0.01) and Rotterdam (OR=1.2, p=0.002) but not Spanish (OR=0.8, p=0.2) population. It should be noted that none of these associations surpassed the Bonferroni cut-off (p<0.0002) for this study (best p=0.0008 for BDNF3 in the Rotterdam dataset).  To determine whether interactions between BDNF polymorphisms could explain the contradictory findings for rs6265 (BDNF1) across multiple populations, we sequentially added pair-wise interactions between the 4 BDNF polymorphisms into the model. No interaction between BDNF polymorphisms was associated with altered AD risk (p>0.5).  Women showed increased susceptibility to AD risk-modifying polymorphisms at the BDNF locus We next tested whether interactions between BDNF polymorphisms and age-at-sampling, sex and possession of the APOE ε4 allele could contribute to AD risk. We found no association of the BDNF1*sex interaction with AD risk (SF=0.95, p=0.9). However, inclusion of BDNF2*sex, BDNF3*sex or BDNF4*sex interactions improved the AIC for the model and the synergy factors (SF) for these interactions are plotted in Fig2A-C. We observed a positive synergistic interaction between BDNF2, BDNF3 and BDNF4 and sex in the total dataset; sex*BDNF2 (SF=1.5, p=0.002), sex*BDNF3 (SF=1.4, p=0.002) and sex*BDNF4 (SF=1.3, p=0.02). The interactions were observed in the Northern European dataset (SF=1.4, p=0.02; SF=1.4, p=0.007; SF=1.3, p=0.02, respectively) and Rotterdam (SF=1.4, p=0.02, SF=1.5; p=0.01, SF=1.4, p=0.04, respectively) datasets and the sex*BDNF2 interaction was also observed in the Spanish 
11  population (SF=1.94, p=0.03). To explore these interactions further, BDNF2-4 were tested for association with AD in women and men separately in the datasets that showed a synergistic interaction (Fig2D-F). While BDNF2 was associated with reduced AD risk in Spanish men (OR=0.6, p=0.03), all three polymorphisms were associated with increased risk in women from the total (BDNF2; OR=1.3, p=0.0006, BDNF3; OR=1.3, p=0.00008, BDNF4; OR=1.2, p=0.007, respectively) and Northern European (OR=1.3, p=0.0007, OR=1.4, p=0.00005, OR=1.2, p=0.001, respectively) and Rotterdam (OR=1.4, p=0.0001, OR=1.4, p=0.00003, OR=1.4, p=0.0002, respectively) datasets, associations that surpassed the Bonferroni cut-off for this study (p<0.0002) in at least one of the datasets.  We next tested for association of interactions between BDNF variants and the APOE ε4 allele. The BDNF3*ε4 interaction (SF=0.47, p=0.02) was associated with altered AD risk in the Spanish dataset and BDNF3 was nominally associated with decreased AD risk in Spanish ε4 carriers (OR=0.58, p=0.05) but not in non-carriers (OR=1.2, p=0.2).  That being said, these interactions may be of less importance since including them in the models did not improve the AIC. Interactions between other BDNF variants and ε4 were not associated with AD risk (p>0.06) and neither were interactions between any BDNF variant and age (p>0.2).  BDNF and DBH polymorphisms act synergistically to increase AD risk in Northern European women  We have previously identified an association of the DBH polymorphism, rs1611115, with increased AD risk in men aged <75 [39] in a sample set that overlaps with that included in this study. Therefore, unsurprisingly, when testing for an association of DBH with AD risk in the total population, we found that the DBH polymorphism was 
12  associated with increased risk of AD in the total dataset (rs1611115T+ OR=1.12, p=0.04), albeit that the association was not apparent in either of the regional subsets (OR=1.1, p=0.1 and OR=1.3, p=0.1). Addition of interactions between the DBH polymorphism and age-at-sampling, sex and possession of the APOE ε4 allele did not improve the AIC for the model. Since DBH and BDNF have both been implicated in regulating noradrenergic neurotransmission, we sought to determine whether polymorphisms at the BDNF and DBH loci could interact to alter AD risk. The addition of interactions between DBH and all 4 BDNF polymorphisms improved the AIC for the model. The SF for the interactions are plotted in Fig3A-D. A synergistic BDNF1*DBH interaction contributed to AD risk in the total (SF=2.2, p=0.007) and Northern European (SF=2.2, p=0.02) and Rotterdam (SF=2.2, p=0.03) datasets. While the SF (SF=1.4) was comparable in the Spanish population (p=0.3), the interaction did not reach our cut-off for significance. Since the BDNF polymorphisms have different effects in men and women, we next tested the BDNF*DBH interactions in male and female subgroups separately. Due to testing rs6265 under a recessive inheritance model, the low number of male MM (rs6265), T+ (rs1611115; dominant model) carriers in the Spanish dataset (n=7), meant that the BDNF*DBH1 interaction could only be tested in the Northern European dataset. In that dataset, the BDNF*DBH1 interaction contributed more to AD risk in women (SF=2.4, p=0.04) than men (SF=2.0, p=0.2). The remaining BDNF*DBH interactions did not contribute to the AD risk (p>0.1) and it should be noted that none of the BDNF1*DBH interactions surpassed the Bonferroni cut-off (p<0.0002) for this study.  
13  SORT1 genetic variation is not associated with AD risk Finally we tested for an association of SORT1 polymorphisms with AD risk. We found no association in the total, Northern European or Spanish populations (p>0.05). We tested for an association of interactions between the SORT1 polymorphisms and age-at-sampling, sex and possession of the APOE ε4 allele with AD risk. We observed an antagonistic interaction between SORT1e (rs1149175 GG) and sex in the Spanish dataset (SORT1e OR=2.2, sex OR=2.1, SF=0.4, p=0.007) and SORT1e was associated with increased AD risk in Spanish men (OR=2.27, p=0.002). That being said, these interactions may be of less importance since including them in the models did not improve the AIC. None of the interactions with the BDNF variants contributed to AD risk in the total or regional subsets (p>0.05).  Discussion This multi-cohort study of 5,682 controls and 2,454 AD patients (recruited from seven research centres from Northern Europe and Spain) represents a comprehensive exploration of the contribution of epistatic interactions between genes encoding proteins implicated in BDNF secretion and noradrenergic innervation to AD risk. The main finding of this study is the synergistic interaction between BDNF risk-modifying variants (BDNF2-4) and sex (SF=1.3 to 1.5) such that the BDNF-associated risk was observed in women (OR=1.2 to 1.3) but not men (OR=0.9 to 1.0). We also show evidence of a synergistic interaction between the BDNF and DBH loci such that carriers of the minor allele at DBH (rs1611115) who are also homozygous for the minor allele at BDNF1 (rs6265) are at increased risk of AD (SF=2.2) than carriers of either allele alone (BDNF OR=1.1 to 1.2, DBH OR=1.1), an effect that was greater in women (SF=2.4) than in men (SF=2.0).  
14  In support of the meta-analyses performed by Alzgene, we report only a nominal association of rs6265 (BDNF1) with AD risk (OR=1.2, p=0.3). On the other hand, we report three novel risk-modifying BDNF polymorphisms that were associated with increased AD risk in the total or Northern European populations (OR=1.1, p<0.01). It should be noted that the OR for rs6265 was similar to that reported for the associations reported for the other 3 polymorphisms. We therefore cannot rule out the possibility that rs6265 has a similar frequency to the other BDNF variants in AD patients, but that the significance of this increased frequency is attenuated by other covariates in the model, namely age-at-collection, sex, APOE ε4 or collection centre Nevertheless, since none of these associations were significant when accounting for multiple testing (lowest p=0.0008, Bonferroni cut-off = 0.0002), these findings warrant replication in large independent cohorts.  The strongest finding of this study is the interaction between BDNF variants 2-4  (rs12288512, rs113030102, rs11030119) and sex (SF=1.3 to 1.5) such that women carriers from Northern Europe were at greater risk of AD (OR=1.3 to 1.4) than men (OR=0.9 to 1.0), associations that were significant even after accounting for multiple testing in at least one dataset. The evidence for the BDNF2*sex interaction reported here is particularly strong, as it was observed in both the Northern European (increased risk in women) and Spanish (decreased in men) subsets as well as the total dataset. This is not the first study to identify sex differences related to the BDNF locus in AD, albeit that a previous study reported an association of BDNF1 (rs6265) with increased AD risk in women from the Han Chinese population [56], a variant that did not interact with sex in this study (p=0.9).  Moreover, the gender effect may not be limited to AD; a greater neuroprotective effect against methamphetamine-induced toxicity (i.e., greater 
15  preservation of corpus striatal dopamine levels) has been reported in male compared to female mice over-expressing Bdnf [57]. In another study, modulation of Bdnf expression in response to acute stress was impaired in female rats [58]. The mechanism underlying the gender difference observed in this and other studies has yet to be fully explored. However, a direct interaction between estrogen receptors and BDNF transcription has been shown to alter hippocampal physiology during development in the rat, suggesting that hormonal variation during a critical time window may contribute to sex-specific effects in BDNF transcription [59]. Whether the BDNF variants reported here also affect BDNF transcription has yet to be explored. If a functional effect is demonstrated, a hypothesis arises whereby BDNF expression may be natively lower in adult women, which, when combined with carrying a genetic variant that may also affect brain BDNF levels, could have a multiplicative effect on susceptibility to AD pathology, thereby increasing risk for AD in female carriers compared to male non-carriers. This is an intriguing avenue worth pursuing in future functional studies.  It is possible that BDNF variants could differentially influence a range of brain regions and networks. Therefore, functional studies to determine how these variants may influence noradrenergic innervation of the hippocampus, frontal cortex, and cerebellum could also be informative. Moreover, whether functional effects can be directly attributed to the polymorphisms included in the study, or rather to other polymorphisms within the linkage disequilibrium blocks that they capture, also warrants further investigation.  We also report a synergistic interaction (SF=2.2) between BDNF1 (rs6265) and DBH1 (rs1611115) that contributed more to AD risk in Northern European women (SF=2.4) than men (SF=2), an association that was not apparent for the other BDNF variants. 
16  This result is particularly intriguing since the rs6265 variant alone showed the weakest association with AD risk. As the interaction did not survive adjustment for multiple testing (p=0.007, Bonferroni cut-off = 0.0002), validation in an independent study is necessary. If validated, this interaction could indicate a combinatorial functional effect between BDNF and DBH variants that is specific to the rs6265 polymorphism, thus highlighting the importance of considering epistatic interactions in genetic studies to unmask otherwise hidden associations with AD. We have previously reported a synergistic interaction between DBH (rs1611115) and pro-inflammatory cytokines [39, 45] that contributed to increased risk for AD. As BDNF and DBH are involved in a feed-forward anti-inflammatory mechanism, these studies could point toward a complex interaction between genes that encode proteins involved in neuroinflammatory pathways and furthermore that these interactions may differ according to sex.  A limitation of this study is the use of Alzheimer’s disease diagnosis as a single end-point, which does not account for the possibility of disease-modifying effects of these variants on brain atrophy or cognitive decline, particularly if these effects are only evident at early stages. The ORs reported in this study, although modest (1.1 to 1.6), suggest a mild effect on AD risk, as would be expected from a complex genetic disorder such as AD.  Overall, these data suggest a complex interplay between BDNF and sex that warrants further investigation in large, independent studies. Acknowledgements The authors are indebted to all the donors and their families for their participation in this study. We would also like to thank the Alzheimer’s Research UK and South West 
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28  Tables Synergy factors  (95% CI, p-value) Population Study [reference] Interacting genes Genotypes All North Europe  North Spain  Combarros O et al 2009 [38] IL6 x IL10 rs2069837 AA x rs1800871 C+ 1.6 (1.1-2.4, 0.01) 1.7 (1.05-2.6, 0.03) 2.0 (0.9-4.4, 0.09) Combarros O et al 2010 [39] DBH x IL1A rs1611115 T+ x rs1800587 TT 1.9 (1.2-3.1, 0.005) 1.7 (1.02-2.8, 0.04) 3.4 (0.9-12.3, 0.07) Lehmann DJ et al 2012 [40] HFE x TF rs1799945 CC x rs1130459 AA 1.5 (1.1-2.1, 0.02) 2.0 (1.3-3.05, 0.002) 1.3 (0.7-2.55, 0.4) Kölsch H et al 2012 [41] PPARA x INS rs1800206 CC x rs689 TT 1.7 (0.9-3.2, 0.1) 2.5 (1.2-5.4, 0.02) 0.8 (0.2-3.0, 0.7) Heun R et al 2012 [42] PPARA x IL1A rs4253766 CC x rs3783550 C+ 1.6 (1.15-2.2, 0.005) 1.7 (1.2-2.5, 0.006) 1.5 (0.7-3.0, 0.3) Bullock JM et al 2012 [43] GSTM3 x HHEX/IDE/KIF11 rs7483 A+ x rs1111875 GG 2.3 (1.6-3.2, < 0.00001)a 2.2 (1.5-3.3, 0.0001)a 2.8 (1.2-6.4, 0.015)a Medway C et al 2013 [44] CYP19A1 x IL10 rs1062033 GG x rs1800896 A+ 1.9 (1.2-3.25, 0.01)b 1.9 (1.1-3.3, 0.02)b 1.4 (0.35-5.55, 0.65)b a in ≥ 75 years (the 3-way interaction with age ±75 years gave p = 0.02) bin women (the 3-way interaction with gender in North Europe gave p = 0.02)  Table 1. Summary of the results obtained from Stage 1 of the Epistasis Project. Synergy Factors and p-values are given for interactions between genes studied in Stage 1. All analyses controlled for age, gender, APOE ε4 and collection centre. Results in bold type are significant at p<0.05. 
29      Age-at-sample-collection (years) Female  APOE ε4+    n Mean +/-SD  range n 75+ n % n % Controls 5682 82+/-8  60-106 4762 3198 56 1303 23   Northern Europe 5239 82+/-7  60-106 4513 2925 56 1231 23     Bristol 88 81+/-8  62-96 69 39 44 12 14     Nottingham 148 78+/-10 60-104 96 65 44 32 22     OPTIMA 208 80+/-7 62-100 154 89 43 49 24     Rotterdam 4795 83+/-7  60-106 4194 2732 57 1138 24   Spain 443 77+/-10  60-104 249 273 62 72 16     Madrid 278 76+/-11  60-104 135 168 60 42 15     Oviedo 59 74+/-5  63-87 29 36 61 12 20     Santander 106 81+/-8  62-99 85 69 65 18 17 AD 2454 81+/-8  60-109 1945 1568 64 1218 50   Northern Europe 1858 83+/-7  60-101 1589 1196 64 926 50     Bristol 210 80+/-9  60-99 160 106 50 137 65     Nottingham 253 83+/-8  61-101 211 140 55 151 60     OPTIMA 267 79+/-8  61-100 190 123 46 178 67     Rotterdam 1128 84+/-6  61-101 1028 827 73 460 41   Spain 596 76+/-8  60-109 356 372 62 292 49     Madrid 232 75+/-10  60-109 106 147 63 118 51     Oviedo 138 77+/-5  63-88 92 86 62 53 38     Santander 226 77+/-7  60-98 158 139 62 121 54  Table 2. Demographics of the sample collections used in this study. The number of samples (n) in each dataset along with mean age-at-sample collection (+/- standard deviation; SD) is given. The sample numbers (n and % of dataset) are also given for the demographic variables included in the analyses, i.e., age-at-collection (participants aged over 75; n>75 versus <75), sex (female versus male) and APOE ε4 carriers (ε4+ versus ε4-).  
30  Region Captured Gene Tag SNP Kbp Region Coverage Polymorphisms r2 rs6265(BDNF1) 0.0 intron,ncRNA,missense 4% rs6265 1.0 rs12288512 (BDNF2) 2.8 near-gene-5 7% rs12288512, rs12273363 0.9-1.0 rs11030102 (BDNF3) 19.8 intron,near-gene-5 7% rs11030102 , rs10835211 0.9-1.0 rs11030119 (BDNF4) 67.2 intron, untranslated-3 30% rs11030119, rs962369, rs7127507, rs1013402, rs11030108, rs7124442, rs1519480, rs925946 0.9-10 rs11030104 (BDNF5) 32.3 intron 15% rs11030104, rs7103411, rs16917237, rs10501087 1.0 rs6265, rs12288512, rs11030104 69.8 intron, ncRNA,missense 4% rs6265, rs11030104, rs12288512, rs1491850 0.9-1.0 rs12288512,rs11030119, rs11030104 5.8 intron 7% rs11030119, rs11030104, rs12288512, rs7934165, rs10767665 0.9-1.0 BDNF;  Coverage = 89% rs11030102, rs11030119, rs11030104 79.5 intron, untranslated-5 15% rs11030119, rs11030104, rs11030102 , rs2203877, rs10835210, rs1519479, rs7931247 0.8-1.0 DBH; Coverage = 3% rs1611115 (DBH1) 0.0 near-gene-5 3% rs1611115 1.0 rs2228604 (SORT1a) 94.8 intron,near-gene-5,coding-synon,untranslated-3 61% rs4603158, rs2228604, rs3879450, rs7518013, rs10745352, rs10858085, rs444387, rs3853501, rs3768497, rs11142, rs10745354, rs10858086, rs10858092, rs4970752, rs4970751, rs1880670, rs443345 0.9-1.0 rs17585355(SORT1b) 0.0 intron 4% rs12037569 1.0 rs7536292(SORT1c) 29.0 intron 7% rs7536292, rs12037569 0.8-1.0 rs17646665(SORT1d) 0.0 intron 4% rs17585355 1.0 rs1149175 (SORT1e) 12.4 intron 7% rs1149175, rs11581665 0.9-1.0 SORT1; Coverage = 86% rs10745354, rs7536292 (SORT1f) 75.6 intron 4% rs10745354, rs7536292, rs464218 0.9-1.0 Table 3. Polymorphisms included in the study. The polymorphisms identified as representative of a linkage disequilibrium block (TagSNP) are listed for each gene. The size (kbp captured), location (region captured) and coverage of the linkage disequilibrium block captured by the TagSNP, known polymorphisms that lie within the LD block (SNPs captured) and the r2 value are listed. The overall coverage of the total gene area is given in the Gene column. 
31  Figures  Figure 1. BDNF main effects on AD risk. The odds ratios (OR) and 95% confidence intervals (CI) are plotted for the main effects of the BDNF polymorphisms on AD risk in A-D. The x-axis is plotted on log-10 scale. P-values <0.05 are labelled next to the corresponding OR. 
32   Figure 2. BDNF interactions with sex. The synergy factors (SF) and 95% confidence intervals (CI) for the interactions between BDNF polymorphisms and sex are plotted (A-C). The odds ratios (OR) and 95% CI for the main effects of BDNF2, BDNF3 and BDNF4 on AD risk in men and women are plotted (D-F). The x-axis is plotted on a log-10 scale. P-values <0.05 are labelled next to the corresponding SF/OR.
33   Figure 3. BDNF interactions with DBH. The synergy factors (SF) and 95% confidence intervals (CI) for the interactions between BDNF1 (A), BDNF2 (B), BDNF3 (C) and BDNF4 (D) with DBH1 are plotted. The x-axis is plotted on a log-10 scale. P-values <0.05 are labelled next to the corresponding SF. 
34  Supplementary Table. The genotype counts and allele frequencies for each polymorphism included in the study. (A) Genotype (Gtype)  and (B) allele frequencies are shown for each polymorphism in controls (CTRL) and AD groups for the total dataset (All), Northern Europe (N.Eur) and Spain datasets as well as individual centres. (A)             Polymorphism Diagnosis Gtype All Bristol Nottingham OPTIMA Rotterdam N.Eur Madrid Oviedo Santander Spain BDNF1 MM 201 2 6 10 164 182 13 3 3 19 rs6265 MV 1777 26 55 63 1499 1643 90 14 30 134  VV 3697 57 87 134 3132 3410 172 42 73 287  N 5675 85 148 207 4795 5235 275 59 106 440  CTRL Gtype rate 1.00 0.97 1.00 1.00 1.00 1.00 0.99 1.00 1.00 0.99  MM 99 10 11 6 42 69 14 6 10 30  MV 764 71 85 100 335 591 61 36 76 173  VV 1576 129 150 161 751 1191 154 94 137 385  N 2439 210 246 267 1128 1851 229 136 223 588  AD Gtype rate 0.99 1.00 0.97 1.00 1.00 1.00 0.99 0.99 0.99 0.99 BDNF2 AA 257 5 5 11 212 233 16 3 5 24 rs12288512 AG 1756 21 54 58 1495 1628 71 18 39 128  GG 3654 54 89 138 3088 3369 187 37 61 285  N 5667 80 148 207 4795 5230 274 58 105 437  CTRL Gtype rate 1.00 0.91 1.00 1.00 1.00 1.00 0.99 0.98 0.99 0.99  AA 106 6 9 16 54 85 13 1 7 21  AG 798 58 88 73 401 620 69 50 59 178  GG 1535 145 149 176 673 1143 149 83 160 392  N 2439 209 246 265 1128 1848 231 134 226 591  AD Gtype rate 0.99 1.00 0.97 0.99 1.00 0.99 1.00 0.97 1.00 0.99 BDNF3 CC 3171 47 75 123 2662 2907 169 36 59 264 rs11030102 GC 2084 24 64 68 1793 1949 78 19 38 135  CTRL GG 399 7 6 16 340 369 17 4 9 30 
35   N 5654 78 145 207 4795 5225 264 59 106 429  Gtype rate 1.00 0.89 0.98 1.00 1.00 1.00 0.95 1.00 1.00 0.97  CC 1314 115 136 145 558 954 136 79 145 360  GC 932 80 86 100 470 736 70 56 70 196  GG 177 8 22 20 100 150 18 1 8 27  N 2423 203 244 265 1128 1840 224 136 223 583  AD Gtype rate 0.99 0.97 0.96 0.99 1.00 0.99 0.97 0.99 0.99 0.98 BDNF4 AA 489 8 13 19 411 451 20 7 11 38 rs11030119 AG 2282 35 60 80 1935 2110 104 21 47 172  GG 2884 39 70 105 2449 2663 145 28 48 221  N 5655 82 143 204 4795 5224 269 56 106 431  CTRL Gtype rate 1.00 0.93 0.97 0.98 1.00 1.00 0.97 0.95 1.00 0.97  AA 219 13 22 24 117 176 23 8 12 43  AG 1011 83 103 104 497 787 80 61 83 224  GG 1194 108 119 138 514 879 123 64 128 315  N 2424 204 244 266 1128 1842 226 133 223 582  AD Gtype rate 0.99 0.97 0.96 1.00 1.00 0.99 0.97 0.96 0.99 0.98 BDNF5 AA 3555 53 83 130 3022 3288 156 40 71 267 rs11030104 GA 1879 25 58 67 1588 1738 95 16 30 141  GG 224 3 6 11 185 205 12 3 4 19  N 5658 81 147 208 4795 5231 263 59 105 427  CTRL Gtype rate 1.00 0.92 0.99 1.00 1.00 1.00 0.95 1.00 0.99 0.96  AA 1502 124 150 153 714 1141 137 90 134 361  GA 812 71 88 102 362 623 69 40 80 189  GG 119 12 14 9 52 87 15 7 10 32  N 2433 207 252 264 1128 1851 221 137 224 582  AD Gtype rate 0.99 0.99 1.00 0.99 1.00 1.00 0.95 0.99 0.99 0.98 DBH CC 3585 55 97 119 3010 3281 194 40 70 304 rs1611115 TC 1828 28 45 79 1560 1712 70 17 29 116  TT 257 3 4 6 225 238 10 2 7 19  N 5670 86 146 204 4795 5231 274 59 106 439  CTRL Gtype rate 1.00 0.98 0.99 0.98 1.00 1.00 0.99 1.00 1.00 0.99 
36   CC 1492 127 156 160 679 1122 149 78 143 370  TC 835 67 85 101 391 644 71 52 68 191  TT 115 11 11 6 58 86 12 4 13 29  N 2442 205 252 267 1128 1852 232 134 224 590  AD Gtype rate 1.00 0.98 1.00 1.00 1.00 1.00 1.00 0.97 0.99 0.99 SORT1 CC 472 6 15 21 399 441 17 6 8 31 rs10745354 CT 2348 36 50 91 1988 2165 108 25 50 183  TT 2846 40 83 93 2408 2624 148 26 48 222  N 5666 82 148 205 4795 5230 273 57 106 436  CTRL Gtype rate 1.00 0.93 1.00 0.99 1.00 1.00 0.98 0.97 1.00 0.98  CC 183 14 17 25 91 147 14 5 17 36  CT 972 87 98 102 463 750 80 53 89 222  TT 1279 108 128 139 574 949 133 79 118 330  N 2434 209 243 266 1128 1846 227 137 224 588  AD Gtype rate 0.99 1.00 0.96 1.00 1.00 0.99 0.98 0.99 0.99 0.99 SORT1 AA 110 2 6 6 89 103 4 0 3 7 rs1149175 AG 1402 20 20 56 1190 1286 69 19 28 116  GG 4160 65 120 142 3516 3843 202 40 75 317  N 5672 87 146 204 4795 5232 275 59 106 440  CTRL Gtype rate 1.00 0.99 0.99 0.98 1.00 1.00 0.99 1.00 1.00 0.99  AA 55 2 4 7 31 44 3 1 7 11  AG 562 61 59 63 252 435 47 24 56 127  GG 1825 147 182 194 845 1368 182 112 163 457  N 2442 210 245 264 1128 1847 232 137 226 595  AD Gtype rate 1.00 1.00 0.97 0.99 1.00 0.99 1.00 0.99 1.00 1.00 SORT1 AA 5047 76 127 182 4259 4644 252 54 97 403 rs17585355 CA 611 10 18 25 526 579 20 4 8 32  CC 15 0 2 1 10 13 1 1 0 2  N 5673 86 147 208 4795 5236 273 59 105 437  CTRL Gtype rate 1.00 0.98 0.99 1.00 1.00 1.00 0.98 1.00 0.99 0.99  AA 2200 191 213 233 1010 1647 216 129 208 553  AD CA 228 18 27 32 113 190 13 9 16 38 
37   CC 9 0 1 1 5 7 1 0 1 2  N 2437 209 241 266 1128 1844 230 138 225 593  Gtype rate 0.99 1.00 0.95 1.00 1.00 0.99 0.99 1.00 1.00 0.99 SORT1 AA 4880 77 131 178 4103 4489 243 51 97 391 rs17646665a GA 759 11 15 29 654 709 33 8 9 50  GG 38 0 0 0 38 38 0 0 0 0  N 5677 88 146 207 4795 5236 276 59 106 441  CTRL Gtype rate 1.00 1.00 0.99 1.00 1.00 1.00 0.99 1.00 1.00 1.00  AA 2162 186 214 243 982 1625 210 127 200 537  GA 268 23 34 21 136 214 20 9 25 54  GG 14 1 1 1 10 13 1 0 0 1  N 2444 210 249 265 1128 1852 231 136 225 592  AD Gtype rate 1.00 1.00 0.98 0.99 1.00 1.00 1.00 0.99 1.00 0.99 SORT1 AA 473 6 15 21 399 441 18 6 8 32 rs2228604a AC 2344 35 49 91 1987 2162 107 25 50 182  CC 2849 40 81 96 2409 2626 148 27 48 223  N 5666 81 145 208 4795 5229 273 58 106 437  CTRL Gtype rate 1.00 0.92 0.98 1.00 1.00 1.00 0.98 0.98 1.00 0.99  AA 182 14 15 25 91 145 15 5 17 37  AC 976 88 97 102 462 749 82 54 91 227  CC 1275 107 126 140 575 948 132 78 117 327  N 2433 209 238 267 1128 1842 229 137 225 591  AD Gtype rate 0.99 1.00 0.94 1.00 1.00 0.99 0.99 0.99 1.00 0.99 SORT1 CC 162 4 5 5 130 144 11 2 5 18 rs7536292a CT 1606 19 46 56 1353 1474 79 20 33 132  TT 3886 61 96 147 3312 3616 165 37 68 270  N 5654 84 147 208 4795 5234 255 59 106 420  CTRL Gtype rate 1.00 0.95 0.99 1.00 1.00 1.00 0.92 1.00 1.00 0.95  CC 81 9 5 12 26 52 13 6 10 29  CT 701 64 70 66 319 519 71 42 69 182  TT 1646 136 169 186 783 1274 142 83 147 372  AD N 2428 209 244 264 1128 1845 226 131 226 583 
38   Gtype rate 0.99 1.00 0.96 0.99 1.00 0.99 0.97 0.95 1.00 0.98  (B)                         Polymorphism Diagnosis Allele All Bristol Nottingham OPTIMA Rotterdam N.Eur Madrid Oviedo Santander Spain BDNF1 M 0.19 0.18 0.23 0.20 0.19 0.19 0.21 0.17 0.17 0.20 rs6265                         CTRL V 0.81 0.82 0.77 0.80 0.81 0.81 0.79 0.83 0.83 0.80   M 0.20 0.22 0.22 0.21 0.19 0.20 0.19 0.18 0.22 0.20                           AD V 0.80 0.78 0.78 0.79 0.81 0.80 0.81 0.82 0.78 0.80 BDNF2  A 0.20 0.19 0.22 0.19 0.20 0.20 0.19 0.21 0.23 0.20 rs12288512                         CTRL G 0.80 0.81 0.78 0.81 0.80 0.80 0.81 0.79 0.77 0.80   A 0.21 0.17 0.22 0.20 0.23 0.21 0.21 0.19 0.16 0.19                           AD G 0.79 0.83 0.78 0.80 0.77 0.79 0.79 0.81 0.84 0.81 BDNF3  C 0.75 0.76 0.74 0.76 0.74 0.74 0.79 0.77 0.74 0.77 rs11030102                         CTRL G 0.25 0.24 0.26 0.24 0.26 0.26 0.21 0.23 0.26 0.23   C 0.73 0.76 0.73 0.74 0.70 0.72 0.76 0.79 0.81 0.79                           AD G 0.27 0.24 0.27 0.26 0.30 0.28 0.24 0.21 0.19 0.21 BDNF4  A 0.29 0.31 0.30 0.29 0.29 0.29 0.27 0.31 0.33 0.29 rs11030119                         CTRL G 0.71 0.69 0.70 0.71 0.71 0.71 0.73 0.69 0.67 0.71   A 0.30 0.27 0.30 0.29 0.32 0.31 0.28 0.29 0.24 0.27                           AD G 0.70 0.73 0.70 0.71 0.68 0.69 0.72 0.71 0.76 0.73 BDNF5  A 0.79 0.81 0.76 0.79 0.80 0.79 0.77 0.81 0.82 0.79 rs11030104                         CTRL G 0.21 0.19 0.24 0.21 0.20 0.21 0.23 0.19 0.18 0.21 
39    A 0.78 0.77 0.77 0.77 0.79 0.78 0.78 0.80 0.78 0.78                           AD G 0.22 0.23 0.23 0.23 0.21 0.22 0.22 0.20 0.22 0.22 DBH  C 0.79 0.80 0.82 0.78 0.79 0.79 0.84 0.82 0.80 0.82 rs1611115                         CTRL T 0.21 0.20 0.18 0.22 0.21 0.21 0.16 0.18 0.20 0.18   C 0.78 0.78 0.79 0.79 0.78 0.78 0.80 0.78 0.79 0.79                           AD T 0.22 0.22 0.21 0.21 0.22 0.22 0.20 0.22 0.21 0.21 SORT1  C 0.29 0.29 0.27 0.32 0.29 0.29 0.26 0.32 0.31 0.28 rs10745354                         CTRL T 0.71 0.71 0.73 0.68 0.71 0.71 0.74 0.68 0.69 0.72   C 0.27 0.28 0.27 0.29 0.29 0.28 0.24 0.23 0.27 0.25                           AD T 0.73 0.72 0.73 0.71 0.71 0.72 0.76 0.77 0.73 0.75 SORT1  A 0.14 0.14 0.11 0.17 0.14 0.14 0.14 0.16 0.16 0.15 rs1149175                         CTRL G 0.86 0.86 0.89 0.83 0.86 0.86 0.86 0.84 0.84 0.85   A 0.14 0.15 0.14 0.15 0.14 0.14 0.11 0.09 0.15 0.13                           AD G 0.86 0.85 0.86 0.85 0.86 0.86 0.89 0.91 0.85 0.87 SORT1  A 0.94 0.94 0.93 0.94 0.94 0.94 0.96 0.95 0.96 0.96 rs17585355                         CTRL C 0.06 0.06 0.07 0.06 0.06 0.06 0.04 0.05 0.04 0.04   A 0.95 0.96 0.94 0.94 0.95 0.94 0.97 0.97 0.96 0.96                           AD C 0.05 0.04 0.06 0.06 0.05 0.06 0.03 0.03 0.04 0.04 SORT1 A 0.93 0.94 0.95 0.93 0.92 0.93 0.94 0.93 0.96 0.94 rs17646665a                         CTRL G 0.07 0.06 0.05 0.07 0.08 0.07 0.06 0.07 0.04 0.06   A 0.94 0.94 0.93 0.96 0.93 0.94 0.95 0.97 0.94 0.95   AD                       
40    G 0.06 0.06 0.07 0.04 0.07 0.06 0.05 0.03 0.06 0.05 SORT1  A 0.29 0.29 0.27 0.32 0.29 0.29 0.26 0.32 0.31 0.28 rs2228604a                         CTRL C 0.71 0.71 0.73 0.68 0.71 0.71 0.74 0.68 0.69 0.72   A 0.28 0.28 0.27 0.28 0.29 0.28 0.24 0.23 0.28 0.25                           AD C 0.72 0.72 0.73 0.72 0.71 0.72 0.76 0.77 0.72 0.75 SORT1  C 0.17 0.16 0.19 0.16 0.17 0.17 0.20 0.20 0.20 0.20 rs7536292a                         CTRL T 0.83 0.84 0.81 0.84 0.83 0.83 0.80 0.80 0.80 0.80   C 0.18 0.20 0.16 0.17 0.16 0.17 0.21 0.21 0.20 0.21                           AD T 0.82 0.80 0.84 0.83 0.84 0.83 0.79 0.79 0.80 0.79   
